首页 | 本学科首页   官方微博 | 高级检索  
检索        

他汀类药物对慢性肝脏疾病进展及预后的影响
引用本文:王帅,张永贵,王江滨,徐严.他汀类药物对慢性肝脏疾病进展及预后的影响[J].临床肝胆病杂志,2021,37(3):721-724.
作者姓名:王帅  张永贵  王江滨  徐严
作者单位:吉林大学中日联谊医院消化内科,长春130033;吉林大学中日联谊医院消化内科,长春130033;吉林大学中日联谊医院消化内科,长春130033;吉林大学中日联谊医院消化内科,长春130033
基金项目:国家自然科学基金(81670533);吉林省教育厅资助项目(JJKH20190067KJ)。
摘    要:慢性肝病严重时可进展为肝纤维化和肝硬化,进而引起门静脉高压,最终可能发展至肝细胞癌。近年来,越来越多的研究发现他汀类药物可以使非酒精性脂肪性肝病患者的肝脏组织学得到改善,延缓肝纤维化进展,降低失代偿事件以及肝细胞癌的发生风险。介绍了他汀类药物在慢性肝病患者中的应用进展,为慢性肝脏疾病的防治提供一定的依据。

关 键 词:肝疾病  羟甲基戊二酰基CoA还原酶抑制剂  治疗结果  预后

Effect of statins on the progression and prognosis of chronic liver diseases
WANG Shuai,ZHANG Yonggui,WANG Jiangbin,XU Yan.Effect of statins on the progression and prognosis of chronic liver diseases[J].Chinese Journal of Clinical Hepatology,2021,37(3):721-724.
Authors:WANG Shuai  ZHANG Yonggui  WANG Jiangbin  XU Yan
Institution:(Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun 130033, China)
Abstract:Chronic liver diseases can progress to liver fibrosis and cirrhosis and may lead to portal hypertension and even hepatocellular carcinoma.In recent years,more and more studies have shown that statins can improve liver histology,delay progression to liver fibrosis,and reduce the risk of decompensation and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.This article introduces the advances in the application of statins in patients with chronic liver diseases,so as to provide a basis for the prevention and treatment of chronic liver diseases.
Keywords:Liver Diseases  Hydroxymethylglutaryl-CoA Reductase Inhibitors  Treatment Outcome  Prognosis
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号